Eli Lilly and Company $LLY Shares Purchased by Ritholtz Wealth Management

Ritholtz Wealth Management raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,139 shares of the company’s stock after purchasing an additional 1,065 shares during the period. Ritholtz Wealth Management’s holdings in Eli Lilly and Company were worth $17,258,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of LLY. PNC Financial Services Group Inc. boosted its stake in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares during the period. Nuveen LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $4,613,912,000. Vanguard Group Inc. lifted its holdings in shares of Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after purchasing an additional 4,975,395 shares during the last quarter. Cohen Investment Advisors LLC boosted its position in Eli Lilly and Company by 7,975.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company’s stock valued at $647,225,000 after purchasing an additional 773,947 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in Eli Lilly and Company by 106.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after buying an additional 765,010 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the transaction, the director owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock valued at $2,894,841 over the last 90 days. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $812.65 on Wednesday. The firm has a 50-day moving average price of $744.36 and a 200 day moving average price of $765.86. The firm has a market capitalization of $769.14 billion, a PE ratio of 53.11, a P/E/G ratio of 1.17 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. dropped their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, September 16th. Berenberg Bank reiterated a “hold” rating and issued a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Leerink Partnrs cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Finally, Guggenheim lifted their price target on Eli Lilly and Company from $875.00 to $948.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $948.06.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.